Pasar al contenido principal

Biomarcadores chivatos de alteraciones en el Alzheimer de la vía apoE y el APP, su validación en modelos celulares (CHIVAT-AD)

PI22/01329

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i en Salud
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION DE LA COMUNIDAD VALENCIANA PARA LA GESTION DEL INST. INV. SANIT. Y BIOMEDICA DE ALICANTE
Centro realización FUNDACION DE LA COMUNIDAD VALENCIANA PARA LA GESTION DEL INST. INV. SANIT. Y BIOMEDICA DE ALICANTE

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Synaptic and extrasynaptic distribution of NMDA receptors in the cortex of Alzheimer's disease patients

  • Escamilla, Sergio
  • Badillos Rodríguez, Raquel|||0000-0002-8257-1784
  • Comella i Carnicé, Joan Xavier|||0000-0002-6218-0786
  • Solé Piñol, Montserrat|||0000-0003-4240-6562
  • Pérez-Otaño, Isabel
  • Sánchez-Mut, José Vicente|||0000-0002-9292-8521
  • Sáez-Valero, Javier
  • Cuchillo-Ibáñez, Inmaculada|||0000-0002-3689-5518
Synaptic and extrasynaptic distribution of N-methyl-D-aspartate receptors (NMDARs) has not been addressed in the brain from Alzheimer's disease (AD) subjects, despite their contribution to neurodegeneration. We have developed a protocol to isolate synaptic and extrasynaptic membranes from controls and AD frontal cortex. We characterized the distribution of the NMDAR subunits GluN2B, GluN2A, GluN1, and GluN3A, as well as post-translational modifications, such as phosphorylation and glycosylation. Lower levels of synaptic GluN2B and GluN2A were found in AD fractions, while extrasynaptic GluN2B and GluN1 levels were significantly higher; GluN3A distribution remained unaffected in AD. We also identified different glycoforms of GluN2B and GluN2A in extrasynaptic membranes. Synaptic Tyr1472 GluN2B phosphorylation was significantly lower in AD fractions. Reduction of synaptic NMDAR subunits, particularly for GluN2B, is likely to contribute to synaptic transmission failure in AD. Additionally, the increment of extrasynaptic NMDAR subunits could favor the activation of excitotoxicity in AD.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

NMDARs in Alzheimer's Disease: Between Synaptic and Extrasynaptic Membranes

  • Escamilla, Sergio
  • Sáez-Valero, Javier
  • Cuchillo-Ibáñez, Inmaculada
N-methyl-D-aspartate receptors (NMDARs) are glutamate receptors with key roles in synaptic communication and plasticity. The activation of synaptic NMDARs initiates plasticity and stimulates cell survival. In contrast, the activation of extrasynaptic NMDARs can promote cell death underlying a potential mechanism of neurodegeneration occurring in Alzheimer's disease (AD). The distribution of synaptic versus extrasynaptic NMDARs has emerged as an important parameter contributing to neuronal dysfunction in neurodegenerative diseases including AD. Here, we review the concept of extrasynaptic NMDARs, as this population is present in numerous neuronal cell membranes but also in the membranes of various non-neuronal cells. Previous evidence regarding the membranal distribution of synaptic versus extrasynaptic NMDRs in relation to AD mice models and in the brains of AD patients will also be reviewed., This research was funded by Fondo de Investigaciones Sanitarias (PI22-01329, co-funded by the Fondo Europeo de Desarrollo Regional, FEDER “Investing in your future”), CIBERNED (Instituto de Salud Carlos III, Spain), ISABIAL (Instituto de Investigación Sanitaria y Biomédica de Alicante), and the Direcció General de Ciència i Investigació, Generalitat Valenciana (AICO/2021/308). We acknowledge financial support from the Spanish Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación, through the “Severo Ochoa” Programme for Centres of Excellence in R&D (CEX2021-001165-S). Sergio Escamilla is funded by the Instituto Carlos III de Madrid (PFIS fellowship)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Synaptic and extrasynaptic distribution of NMDA receptors in the cortex of Alzheimer's disease patients

  • Escamilla, Sergio
  • Badillos, Raquel
  • Comella, Joan X.
  • Solé, Montse
  • Pérez-Otaño, Isabel
  • Sánchez-Mut, José Vicente
  • Sáez-Valero, Javier
  • Cuchillo-Ibáñez, Inmaculada
[Background] Synaptic and extrasynaptic distribution of N-methyl-D-aspartate receptors (NMDARs) has not been addressed in the brain from Alzheimer´s disease (AD) subjects, despite their contribution to neurodegeneration., [Methods] We have developed a protocol to isolate synaptic and extrasynaptic membranes from controls and AD frontal cortex. We characterized the distribution of the NMDAR subunits GluN2B, GluN2A, GluN1, and GluN3A, as well as post-translational modifications, such as phosphorylation and glycosylation., [Results] Lower levels of synaptic GluN2B and GluN2A were found in AD fractions, while extrasynaptic GluN2B and GluN1 levels were significantly higher; GluN3A distribution remained unaffected in AD. We also identified different glycoforms of GluN2B and GluN2A in extrasynaptic membranes. Synaptic Tyr1472 GluN2B phosphorylation was significantly lower in AD fractions., [Discussion] Reduction of synaptic NMDAR subunits, particularly for GluN2B, is likely to contribute to synaptic transmission failure in AD. Additionally, the increment of extrasynaptic NMDAR subunits could favor the activation of excitotoxicity in AD., We particularly want to acknowledge patients and Biobank HUB-ICO-IDIBELL (PT20/00171) integrated in the ISCIII Biobanks and Biomodels Platform and Xarxa Banc de Tumors de Catalunya (XBTC) for their collaboration. This work was supported by grants from the Fondo de Investigaciones Sanitarias (PI22/01329, co-funded by the Fondo Europeo de Desarrollo Regional, FEDER “Investing in your future”), CIBERNED (Instituto de Salud Carlos III, Spain), and from the Direcció General de Ciència i Investigació, Generalitat Valenciana (AICO/2021/308). Sergio Escamilla is supported by a PFIS fellowship from the ISC-III, Centro de Excelencia Severo Ochoa, Agencia Estatal de Investigación (CEX2021-001165-S), Instituto de Investigación Sanitaria y Biomédica de Alicante (Isabial), and Programa Investigo, Conselleria de Innovación, Universidades, Investigación y Sociedad Digital, Generalitat Valenciana ( INVEST-2023-157)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Risk for COVID-19 Vulnerability in Patients with Inflammatory Bowel Disease: Assessing Alterations in ACE2 and TMPRSS2

  • Sáez-Leyva, Jorge
  • Lennol, Matthew P.
  • Avilés-Granados, Carlos
  • García-Ayllón, María-Salud
  • Sáez-Valero, Javier
Chronic inflammatory conditions often involve the dysregulation of key enzymes, including serine proteases such as transmembrane serine protease 2 (TMPRSS2) and the angiotensin converting enzyme 2 (ACE2), which are key proteins implicated in the cellular entry mechanism of SARS-CoV-2. It remains uncertain whether the gastrointestinal symptoms observed in COVID-19 patients result from direct viral infection of the gastrointestinal tract, a process that may be exacerbated by altered expression of ACE2 or TMPRSS2. In this review, we explore the interplay among ACE2 and TMPRSS2 in the context of inflammatory bowel disease (IBD), including their roles in disease pathology and response to therapy. We also examine methodological approaches for assessing whether protease alterations contribute to increased susceptibility to infection, considering that TMPRSS2 exists in inactive (zymogen) and active forms. Furthermore, while membrane-bound ACE2 facilitates viral entry, soluble ACE2 fragments may act as decoys, preventing virus–receptor interaction. Therefore, the interpretation of changes in full-length versus cleaved forms of ACE2 and related enzymes is critical for understanding vulnerability to SARS-CoV-2 infection., This work was supported by grants from the Fondo de Investigaciones Sanitarias (PI22/01329, co-funded by the Fondo Europeo de Desarrollo Regional, FEDER “Investing in your future”), CIBERNED (Instituto de Salud Carlos III, Spain), from the Direcció General de Ciència i Investigació, Generalitat Valenciana (AICO/2021/308) and “Severo Ochoa” Program for Centers of Excellence in R&D (CEX2021-001165-S). CAG is supported by a predoctoral contract (PRE2022-104182) funded by the Agencia Estatal de Investigación (AEI) and the Ministerio de Ciencia e Innovación (MCIN) under the Plan Estatal de I + D + I 2021–2023, co-funded by the European Social Fund (FSE)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Development and Validation of an ICP-MS/MS Method for the Multielemental Analysis of Cerebrospinal Fluid, Examination of Alzheimer's Disease Samples

  • Pérez-Ramírez, Rebeca
  • Cuchillo-Ibáñez, Inmaculada
  • Sánchez-Romero, Raquel
  • Beltrán-Sanahuja, Ana
  • Escamilla, Sergio
  • Molina-Gasset, Ricardo
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Sáez-Valero, Javier
  • Todolí-Torró, José Luis
Multielemental analysis of cerebrospinal fluid (CSF) yields critical insights into the pathophysiology of neurological disorders and holds potential as a diagnostic and predictive tool for Alzheimer's disease (AD). The present work presents the development and validation of an inductively coupled plasma tandem mass spectrometry (ICP-MS/MS) based method for multielemental determination in CSF, including metals and metalloids as analytes. As a proof of concept, the importance of the CSF element determination was evaluated in a cohort of patients with AD (n = 20) and non-AD controls (n = 19) who displayed typical levels of core CSF biomarkers (Aβ42, P-tau, and total-tau). Discrete sample introduction ICP-MS/MS procedure was effective for accurate and precise CSF analysis. The methodology provided better sensitivities and limits of detection than a conventional one based on sample dilution and analysis in continuous sample introduction mode, while only requiring a 20 μL CSF sample volume. A total of 24 elements were encountered and quantified in CSF, with reduced levels of Mn, Cr, Se, Fe, and Zn in the CSF from AD patients and increased levels of Ag and Bi, compared with non-AD patients. Particularly, Mn fully discriminated AD from non-AD subjects, with binary regression analysis indicating that Mn was the most effective element to distinguish between AD and non-AD groups. Furthermore, distinctive correlation profiles were found between AD and non-AD controls for elements with AD core biomarkers and the alternative amyloidogenic sAPPβ fragment. Quantitative determination of metals, metalloids and non-metals displays differences associated with pathological status, serving as additional biomarkers for neurological diseases., The authors wish to thank the Spanish State Research Agency (AEI) from the Ministry of Science, Innovation, and Universities for the financial support (Project Ref. PID2021-127566NB-I00). This work was also supported by grants from the Fondo de Investigaciones Sanitarias (PI22/01329, co-funded by the Fondo Europeo de Desarrollo Regional, FEDER “Investing in your future”), CIBERNED (Instituto de Salud Carlos III, Spain), the Direcció General de Ciència i Investigació, Generalitat Valenciana (AICO/2021/308) and by the Spanish State Research Agency (AEI/10.13039/501100011033), through the “Severo Ochoa” Center of Excellence grant to the IN (CEX2021-001165-S). SE is supported by a PFIS fellowship from the ISC-III. H.Z. is a Wallenberg scholar and a distinguished professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356, #2022-01018, and #2019-02397), the European Union's Horizon Europe research and innovation program under grant agreement No 101053962, and Swedish State Support for Clinical Research (#ALFGBG-71320)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

GluN2A-mediated currents and calcium signal in human iPSC-derived neurons

  • Escamilla, Sergio
  • Avilés-Granados, Carlos3
  • Peralta, Francisco Andrés
  • Paternain, Ana V.
  • Cortés‐Gómez, Maria‐Angeles
  • Zetterberg, Henrik
  • Peña, Elvira de la
  • Salas-Lucia, Federico
  • Sáez-Valero, Javier
  • Cuchillo-Ibáñez, Inmaculada
Gene expression data indicate that during human brain development, neurons change the NMDA receptor (NMDAR) subunit composition to modulate their function, favouring the GluN2A subunit over GluN2B-a hallmark of neuronal maturation. However, evidence supporting this phenomenon in human iPSC-derived neurons remains elusive. Here, using two differentiation methods in parallel (BrainPhys Neuronal Medium, BPM, and Neural Maintenance Medium, NMM), we provide evidence of increased synaptic localization of NMDARs during neuronal maturation and that GluN2A subunit is crucial for the NMDA physiological function-inducing inward currents and calcium entrance at 60 days of differentiation. Calcium responses to specific agonists, particularly NMDA, were elevated in cells cultured under BPM conditions. This is likely attributable to their more mature neuronal phenotype and the RNA-seq identified upregulation of genes involved in intracellular calcium signaling proteins. Our results offer insight into how glutamate receptor subunits mature during brain development, delineating approaches to study NMDAR activity in health and disease., This work was supported by grants from the Fondo de Investigaciones Sanitarias (PI22/01329, co-funded by the Fondo Europeo de Desarrollo Regional, FEDER “Investing in your future”), CIBERNED (Instituto de Salud Carlos III, Spain), the Instituto de Investigación Sanitaria y Biomédica de Alicante (Isabial), Direcció General de Ciència i Investigació, Generalitat Valenciana (CIAICO/2024/313) and “Severo Ochoa” Program for Centers of Excellence in R&D (CEX2021-001165-S). SE is supported by a PFIS fellowship from the ISC‐III. CAG is supported by a predoctoral contract. (PRE2022-104182) funded by the Agencia Estatal de Investigación (AEI) and the Ministerio de Ciencia e Innovación (MCIN) under the Plan Estatal de I + D+I 2021–2023, co-funded by the European Social Fund (FSE). FS-L is supported by University of Chicago start-up funds. AVP is supported by the Spanish Agency of Research (AEI) under the grants PID2022-136741NB-100 and by the Generalitat Valenciana through the program PROMETEO/2019/014 and CIPROM/2022/08 to Juan Lerma. EDLP and FAP are supported by grant PID2022-140961OB-100 (MCIN/AEI/https://doi.org/10.13039/501100011033), grant PROMETEO/2021/031 (Generalitat Valenciana Government) and “Severo Ochoa” Program for Centers of Excellence in R&D (CEX2021-001165-S). HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023 − 00356, #2022 − 01018 and #2019–02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, and Swedish State Support for Clinical Research (#ALFGBG-71320)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Selective reduction of ADAM10 in brain and cerebrospinal fluid of Alzheimer's disease patients

  • Gea-González, Adriana
  • Valle-Pedroso, Renata
  • López-Font, Inmaculada
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Sáez-Valero, Javier
  • García-Ayllón, María-Salud
ADAM10 and ADAM17, members of the membrane-bound disintegrin metalloproteinase (ADAM) family, act as α-secretases in the non-amyloidogenic processing of the amyloid precursor protein. While alterations in ADAM10, the primary α-secretase, have been reported in Alzheimer’s disease (AD), with certain controversy between studies, ADAM17 changes remain less understood. Both enzymes display a complex pattern of expression that includes immature zymogen and mature full-length, assigned as the active form, and soluble cleaved species. We reported for the first time that ADAM10 is present in human cerebrospinal fluid (CSF), and levels of the full-length and soluble fragments decrease in samples from AD patients., This work was supported by grants from Fundació para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (UGP-21-217 to M-S.G-A.); Fondo de Investigaciones Sanitarias (PI22/01329 to J.S-V and PI24/01421 to M-S.G-A)co-funded by the Fondo Europeo de Desarrollo Regional, FEDER “Investing in your future”); CIBERNED (Instituto de Salud Carlos III, Spain); Direcció General de Ciència i Investigació, Generalitat Valenciana (CIAICO/2024/313 to J.S-V). HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023 − 00356, #2022 − 01018 and #2019–02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809–2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, the UK Dementia Research Institute at UCL (UKDRI-1003), and an anonymous donor. KB is supported by the Swedish Research Council (#2017 − 00915 and #2022 − 00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, and #AF-994551), Hjärnfonden, Sweden (#ALZ2022-0006, #FO2024-0048-TK-130 and FO2024-0048-HK-24), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-965240 and #ALFGBG-1006418), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022–2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, Familjen Rönströms Stiftelse, Stockholm, Sweden. R-V.P. was supported by São Paulo Research Foundation (FAPESP, grants 2019/20110-1 and #2017/18808-5). A.G-G. was supported by a PhD fellowship (grant CIACIF/2021/426) funded by the Conselleria of Education, Culture, Universities and Employment (Generalitat Valenciana) and co-funded by the European Union through the Fondo Social Europeo (FSE)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cell-based regenerative interventions in Parkinson's disease: Overcoming pharmacological limitations

  • Padilla, Ana Lizeth
  • Lanciego, José Luis
  • Vila, Miquel
  • Castro Soubriet, Fernando de
  • Pozo, David
  • Rodríguez de Fonseca, Fernando
  • Serrano, Antonia
  • Sáez-Valero, Javier
  • Núñez, Lucía
  • Villalobos, Carlos
  • Tapias, Víctor
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic (DA) neurons and the pathological aggregation of α-synuclein. While current pharmacological therapies provide symptomatic relief, they do not halt or reverse disease progression. Cell-based regenerative strategies have emerged as promising approaches to restore DA function and target the complex, multifactorial pathophysiology of PD. This review critically examines current approaches, including transplantation of fetal ventral mesencephalic tissue, pluripotent stem cell-derived midbrain DA progenitors, and in vivo reprogramming of endogenous cells. In addition, supportive cell types, such as mesenchymal stromal cells and carotid body glomus cells, provide neuroprotective and immunomodulatory effects via paracrine signaling. We summarize preclinical and clinical evidence on graft survival, integration, and functional recovery, and discuss key determinants of therapeutic efficacy, including mitochondrial function and bioenergetic integrity, immune compatibility, and biomaterial scaffolding. Despite significant progress, major challenges remain regarding long-term efficacy, graft standardization, and host-graft interactions. Ongoing translational advances are poised to drive the development of disease-modifying cell therapies capable of delivering durable clinical benefits and improving long-term outcomes in PD., This work was supported by the Aligning Science Across Parkinson's (#ASAP-020505, USA) through the Michael J. Fox Foundation for Parkinson's Research (MJFF), Ministerio de Ciencia, Innovación y Universidades y Agencia Estatal de Investigación (MICIN/AEI, #PID2020-120308RB, Spain), CiberNed Intramural Collaborative Projects (#PI2020/09, Spain) and Fundación Mutua Madrileña de Investigación Médica (#FMM2020, Spain) to José L. Lanciego; Aligning Science Across Parkinson's (#ASAP-020505, USA) through the MJFF (USA), MICIN/AEI (#PID2020-116339RB-I00, Spain) to Miquel Vila; MICIN/AEI (#PID2022-143110OB-100, Spain), Fundación Ramón Areces (#CIVP19A5917, Spain), Fundación Merck Salud (2023, Spain) and Fundación Grupo de Afectados por Esclerosis Multiple (GAEM, #050601240006, Spain) in collaboration with research networks #RED2022-134081-T and #RED2022-134425-T to Fernando de Castro; MICIN/AEI (#PI22/00427 and #PI20/01399, Spain) and European Regional Development Funds-European Union (ERDF-EU) to Fernando Rodríguez de Fonseca and Antonia Serrano; MICIN/AEI (#RTI2018-098432-BI00), Junta de Andalucía (#PI-232-2022 and #CTS-677), Fundació Catalana d’ELA Miquel Valls (2022, Spain), Fundación Juntos contra la ELA (2023, Spain) to David Pozo; Fondo de Investigaciones Sanitarias (#PI22/01329, Spain), Fondo Europeo de Desarrollo Regional (FEDER), and Dirección General de Ciencia e Investigación de la Generalitat Valenciana (CIAICO/2024/313, Spain) to Javier Sáez-Valero; Excellence Program from Junta de Castilla y León (#CCVC8485, Spain) and MICIN/AEI (#PID2021-125909OB-100, Spain) to Carlos Villalobos and Lucía Núñez, and Junta de Castilla y León (#VA294P18, Spain) to Lucía Núñez; María Zambrano's Excellence Program from the MICIN/AEI (#CONVREC-2021-278, Spain), University of Valladolid and the Internationalization program of Junta de Castilla y León (#CL-EI-2021-09, Spain) to Victor Tapias., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cerebrospinal fluid and frontal cortex TMPRSS2 and ACE2 protein levels differ in Down syndrome and Alzheimer's disease

  • Avilés-Granados, Carlos
  • Gea-González, Adriana
  • Sáez-Leyva, Jorge
  • Pérez, Sylvia E.
  • Mufson, Elliott J.
  • Granholm, Ann-Charlotte
  • Carmona-Iragui, María
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Fortea, Juan
  • García-Ayllón, María-Salud
  • Sáez-Valero, Javier
Individuals with Down syndrome (DS) and Alzheimer’s disease (AD) are vulnerable to COVID-19, but whether alterations in ACE2, the viral receptor, and TMPRSS2, the spike-priming protease for SARS-CoV-2, differ between these disorders is unknown. We analyzed cleaved fragments and full-length species of ACE2 and TMPRSS2 in the cerebrospinal fluid (CSF) from non-infected individuals with DS (n = 9) without memory decline (nDS), DS with dementia (dDS; n = 10) and aged matched controls (n = 10). CSF levels were compared to levels in frozen postmortem frontal cortex in nDS (n = 4), dDS (n = 8) and 11 controls using quantitative fluorescent western blotting. We also examined CSF (19 AD and 19 age-matched non-AD controls) and frontal cortex from 30 AD cases and 7 non-disease controls. CSF and frontal cortex TMPRSS2 full-length zymogen and active protease-domain fragment were significantly increased in nDS, but not in dDS despite elevated zymogen. In contrast, AD CSF and frontal cortex levels of the TMPRSS2 protease fragment and zymogen remained unchanged. Regarding the viral receptor, an ~ 80 kDa fragment of ACE2 was significantly reduced in nDS CSF compared to controls, whereas there was a significant decrease in an ACE2 fragment/full-length quotient in both nDS and dDS. In frontal cortex, full-length ACE2 levels were preserved in nDS compared to controls, but several ACE2 species (120 and 110 kDa full-length, and 80 kDa fragment) were significantly decreased in dDS compared to nDS and controls. In contrast, CSF ACE2 130 kDa full-length levels were decreased compared to an increase in the fragment/full-length ratio in AD compared to controls, opposite to DS. In AD, frontal cortex levels of the 150 kDa ACE2 full-length species was significantly reduced across all Braak stages. ACE2 immunohistochemistry and immunofluorescence of frontal cortex sections revealed positive puncta in the neuropil, astrocytes and blood vessels in AD and DS with or without dementia. Overall, we found an increase in active TMPRSS2 and reduced soluble ACE2 fragments individuals with DS, particularly those without dementia, which differs from that observed in AD that may differentially affect susceptibility to COVID-19 viral infection in these conditions., This work was supported by grants from the Fondo de Investigaciones Sanitarias (PI22/01329, co-funded by the Fondo Europeo de Desarrollo Regional, FEDER “Investing in your future”), CIBERNED (Instituto de Salud Carlos III, Spain), from the Direcció General de Ciència i Investigació, Generalitat Valenciana (CIAICO/2024/313) and “Severo Ochoa” Program for Centers of Excellence in R&D (CEX2021-001165-S). CAG is supported by a predoctoral contract (PRE2022-104182) funded by the Agencia Estatal de Investigación (AEI) and the Ministerio de Ciencia e Innovación (MCIN) under the Plan Estatal de I + D+I 2021–2023, co-funded by the European Social Fund (FSE). A.G-G. was supported by a PhD fellowship (grant CIACIF/2021/426) funded by the Conselleria of Education, Culture, Universities and Employment (Generalitat Valenciana) and co-funded by the European Union through the Fondo Social Europeo (FSE). HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023 − 00356, #2022 − 01018 and #2019–02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809–2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (#2017 − 00915 and #2022 − 00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, and #AF-994551), Hjärnfonden, Sweden (#ALZ2022-0006, #FO2024-0048-TK-130 and FO2024-0048-HK-24), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-965240 and #ALFGBG-1006418), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022–2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, Familjen Rönströms Stiftelse, Stockholm, Sweden. EM and SEP are supported by grants from the NIA PO1AG014449, RF1AG081286, R01AG061566), BrightFocus Foundation (CA2018010), Arizona Alzheimer’s Consortium, Barrow Neurological Foundation. ACG was supported by NIH grants (5 R01 AG071228-02, R01AG070153, 1U24AG092191-01, and 5 R01 AG061566) and by a Foundation Lejeune grant to the DSBC brain bank consortium (GRT-2023b/2277). The researchers also acknowledge the support of anonymous philanthropists and donors., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Meprin-β levels are increased in the brain and the cerebrospinal fluid of Alzheimer's disease patients

  • Escamilla, Sergio
  • Avilés-Granados, Carlos
  • Márquez Marco, Carmen
  • Keller, Maximilian
  • Sánchez-Domínguez, Irene
  • Cuchillo-Ibáñez, Inmaculada
  • Aguado, Fernando
  • Zetterberg, Henrik
  • Pietrzik, Claus U.
  • Sáez-Valero, Javier
The aim of this study is to assess the levels of meprin-β, an alternative β-secretase in the brain and cerebrospinal fluid of subjects suffering Alzheimer's disease. The full-length zymogen and the active species of meprin-β were characterized by immunoblotting and immunoprecipitation using ectodomain N-terminal and C-terminal antibodies. We examined meprin-β changes in extracts from Alzheimer's frontal cortex (n = 13, Braak stages I-II; n = 12, Braak stages III-IV; n = 12, Braak stages V-VI) compared with controls (n = 14), as well as in cerebrospinal fluid samples from Alzheimer's patients (n = 15) or non-Alzheimer's controls (n = 15). Cerebrospinal fluid meprin-β levels were also determined in 19-month old TgF344-AD and wild-type rats. Brain and cerebrospinal fluid from a Mep1b-null mouse served to characterize the specificity of the immunoreactive bands for meprin-β. Human induced pluripotent stem cell (iPSC)-derived neuronal cultures were treated with 2 μM Aβ42 for 24 h. We found that meprin-β is present in human brain extracts and cerebrospinal fluid as several distinct species, attributed to the zymogen and the mature species. These species were absent in brain and cerebrospinal fluid from a Mep1b-null mouse. No fragments of meprin-β were detected in brain extract, either in cerebrospinal fluid. Only the mature forms of meprin-β are increased in frontal cortex extracts (from Braak V-VI), but not the zymogen. The MEP1-B mRNA levels are increased in Braaks III-IV and V-VI compared with controls. The meprin-β species are increased in human neuronal cultures treated with Aβ42. Finally, we demonstrated elevated levels of the mature meprin-β in the cerebrospinal fluid of patients with Alzheimer's disease and in TgF344-AD rats. Our data support a role of meprin-β in Alzheimer's pathology., This work was supported by grants from the Fondo de Investigaciones Sanitarias (PI22/01329, co-funded by the Fondo Europeo de Desarrollo Regional, FEDER “Investing in your future”), CIBERNED (Instituto de Salud Carlos III, Spain), from the Direcció General de Ciència i Investigació, Generalitat Valenciana (CIAICO/2024/313), and “Severo Ochoa” Program for Centers of Excellence in R&D (CEX2021-001165-S). SE is funded by the Instituto de Salud Carlos III (PFIS fellowship). This study was also supported by the by the Spanish Ministry of Science, Innovation and Universities MICINN/FEDER (PID2022-142187OB-I00), to FA. CAG is supported by a predoctoral contract (PRE2022-104182) funded by the Agencia Estatal de Investigación (AEI) and the Ministerio de Ciencia e Innovación (MCIN) under the Plan Estatal de I + D + I 2021–2023, co-funded by the European Social Fund (FSE). HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023–00356, #2022–01018 and #2019–02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201,809–2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21–831,376-C, #ADSF-21–831,381-C, #ADSF-21–831,377-C, and #ADSF-24–1,284,328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, the UK Dementia Research Institute at UCL (UKDRI-1003)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed